Señales en vivo de BIIB | Maximiza tus Ganancias con Getagraph.com

COMPRAR 2133 min ago

@ $208.76

Emitido: 26 abr 2024 @ 15:56

Retorno: 0.07%

Señal anterior: abr 26 - 10:13

Señal anterior: Vender

Retorno: 1.91 %

Live Chart Being Loaded With Signals

Commentary (26 abr 2024 @ 16:00):
Our systems believe the stock currently is undervalued by 0.28% compare to its pairs and should correct upwards.

Stats
Volumen de hoy	1.89M
Volumen promedio	1.27M
Capitalización de mercado	30.42B
EPS	$0 ( 2024-04-24 )
Próxima fecha de ganancias	( $3.97 ) 2024-07-23
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	26.11
ATR14	$11.62 (5.56%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-02	Singhal Priya	Sell	93	Common Stock
2024-04-01	Murphy Nicole	Buy	240	Common Stock
2024-04-01	Murphy Nicole	Sell	117	Common Stock
2024-04-01	Murphy Nicole	Sell	240	Restricted Stock Unit
2024-02-22	Singhal Priya	Sell	262	Common Stock

INSIDER POWER
4.52
Last 100 transactions
Buy: 80 749 \| Sell: 73 436

Correlación (AI algo v.1.1b): Undervalued: 0.28% $209.47 paired level. (El Algoritmo Rastrea Los Cambios De Las Acciones Más Correlacionadas En Tiempo Real Y Proporciona Una Actualización Instantánea)

Volumen Correlación

Largo: 0.15 (neutral)

Corto: -0.40 (neutral)

Signal:(35) Neutral

Biogen Inc Correlación

10 Correlaciones Más Positivas
EVCM	0.883
RBNC	0.879
NLTX	0.879
ACLX	0.878
EGRX	0.873
ARCT	0.865
HBIO	0.863
NATI	0.862
FCFS	0.861
MDLZ	0.858

10 Correlaciones Más Negativas
NYMTN	-0.908
WTRE	-0.908
RNMC	-0.903
REIT	-0.903
KBWD	-0.9
SDVY	-0.899
NEOG	-0.899
FFBW	-0.898
XT	-0.895
ICHR	-0.895

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Biogen Inc Correlación - Moneda/Commodity

-0.63
( weak negative )

-0.49
( neutral )

0.00
( neutral )

-0.25
( neutral )

-0.08
( neutral )

0.48
( neutral )

Biogen Inc Finanzas

Annual	2023
Ingresos:	$9.84B
Beneficio Bruto:	$7.30B (74.24 %)
EPS:	$8.02

FY	2023
Ingresos:	$9.84B
Beneficio Bruto:	$7.30B (74.24 %)
EPS:	$8.02

FY	2022
Ingresos:	$10.17B
Beneficio Bruto:	$7.90B (77.61 %)
EPS:	$20.97

FY	2021
Ingresos:	$10.98B
Beneficio Bruto:	$8.87B (80.79 %)
EPS:	$10.44

Financial Reports:

No articles found.

Biogen Inc

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.